FEBS Letters · 2005 · 89 citations · 35 references
Life SciencesCell BiologyPharmacologyCell SignalingMembrane TraffickingSignal TransductionCannabinoid PharmacologyLigand BindingLipid RaftsLipid-protein InteractionsMembrane DomainsProtein-lipid InteractionsCannabinoid AgonistsCannabinoid Receptor DistributionCannabinoid Receptor ModulationCholesterol-dependent DomainsLysosomal CompartmentalizationMembrane Cholesterol DistributionRaft-associated ReceptorsReceptors
In this report we show, by confocal analysis of indirect immunofluorescence, that the type-1 cannabinoid receptor (CB1R), which belongs to the family of G-protein-coupled receptors, is expressed on the plasma membrane in human breast cancer MDA-MB-231 cells. However, a substantial proportion of the receptor is present in lysosomes. We found that CB1R is associated with cholesterol- and sphyngolipid-enriched membrane domains (rafts). Cholesterol depletion by methyl-beta-cyclodextrin (MCD) treatment strongly reduces the flotation of the protein on the raft-fractions (DRM) of sucrose density gradients suggesting that CB1 raft-association is cholesterol dependent. Interestingly binding of the agonist, anandamide (AEA) also impairs DRM-association of the receptor suggesting that the membrane distribution of the receptor is dependent on rafts and is possibly regulated by the agonist binding. Indeed MCD completely blocked the clustering of CB1R at the plasma membrane. On the contrary the lysosomal localization of CB1R was impaired by this treatment only after AEA binding.
35